Download PDF
Exp Clin Endocrinol Diabetes 2023; 131(05): 290-298
DOI: 10.1055/a-2045-7787
Article

Fasting Plasma Glucose Levels at the Time of Admission Predict 90-Day Mortality in Patients with Viral Pneumonia. A Prospective Study

Jie Xu
1   Department of Respiratory and Critical Care Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, China
,
Jianyu Zhao
2   Department of Laboratory Medicine, Shunyi District Hospital of Beijing, Beijing, China
,
Liyuan Wu
3   Department of Laboratory Medicine, Guangzhou Women and Children's Medical Center, Guangzhou, China
,
Xinxin Lu
4   Department of Laboratory Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, China
› Author Affiliations Funding This study was supported by the research on the pathogenic diagnosis of acute and severe respiratory infectious diseases in general hospitals (2014ZX10004005) and research on relevant technical specifications and standard systems of biosafety sample banks (SQ2019YFC120021).
› Further Information
Also available at
    Permissions and Reprints

Abstract

Purpose To determine the effect of fasting plasma glucose (FPG) level at admission affects the 90-day mortality rate in patients with viral pneumonia.

Methods Two hundred fifty viral pneumonia patients were stratified into normal FPG (FPG<7.0 mmol/L), moderately-elevated FPG (FPG=7.0–14.0 mmol/L), and highly-elevated FPG groups (FPG≥14.0 mmol/L) according to the FPG level at the time of admission. The clinical characteristics, etiologies, and prognosis of different groups of patients were compared. Kaplan-Meier survival and Cox regression analyses were used to determine the relationship between the FPG level and 90-day all-cause mortality rate in patients with viral pneumonia.

Results Patients in the moderately- and highly-elevated FPG groups had a higher proportion of severe disease and mortality compared with the normal FPG group (P<0.001). Kaplan-Meier survival analysis showed a significant trend toward higher mortality and increased cumulative risk at 30, 60, and 90 d in patients with an FPG=7.0–14.0 mmol/L and an FPG≥14 mmol/L (χ2=51. 77, P<0.001). Multivariate Cox regression analysis revealed that compared with an FPG<7.0 mmol/L, FPG=7.0 and 14.0 mmol/L (HR: 9.236, 95% CI: 1.106–77.119, P=0.040) and FPG≥14.0 mmol/L (HR: 25.935, 95% CI: 2.586–246.213, P=0.005) were independent risk factors for predicting the 90-day mortality rate in viral pneumonia patients.

Conclusions The higher the FPG level at admission in a patient with viral pneumonia, the higher the risk of all-cause mortality within 90 d.

Key words

viral pneumonia - fasting plasma glucose level - type 2 diabetes - survival analysis


Publication History

Received: 29 November 2022
Received: 17 February 2023

Accepted: 16 February 2023

Article published online:
17 May 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Arnold FW, Fuqua JL.. Viral respiratory infections: A cause of community-acquired pneumonia or a predisposing factor?. Curr Opin Pulm Med 2020; 26: 208-214
    CrossrefPubMedGoogle Scholar
  • 2 Kornum JB, Thomsen RW, Riis A. et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: A population-based case-control study. Diabetes Care 2008; 31: 1541-1545
    CrossrefPubMedGoogle Scholar
  • 3 Lepper PM, Ott S, Nüesch E. et al. Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: Prospective cohort study. BMJ 2012; 344: e3397
    CrossrefPubMedGoogle Scholar
  • 4 Liu SP, Zhang Q, Wang W. et al. Hyperglycemia is a strong predictor of poor prognosis in COVID-19. Diabetes Res Clin Pract 2020; 167: 108338
    CrossrefPubMedGoogle Scholar
  • 5 Lepper PM, Bals R, Jüni P. et al. Blood glucose, diabetes and metabolic control in patients with community-acquired pneumonia. Diabetologia 2020; 63: 2488-2490
    CrossrefPubMedGoogle Scholar
  • 6 Bode B, Garrett V, Messler J. et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol 2020; 14: 813-821 [erratum in J Diabetes Sci Technol]
    CrossrefPubMedGoogle Scholar
  • 7 Zhu L, She ZG, Cheng X. et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020; 31: 1068-1077.e3
    CrossrefPubMedGoogle Scholar
  • 8 Chang MC, Hwang JM, Jeon JH. et al. Fasting plasma glucose level independently predicts the mortality of patients with coronavirus disease 2019 infection: A multicenter, retrospective cohort study. Endocrinol Metab (Seoul) 2020; 35: 595-601
    CrossrefPubMedGoogle Scholar
  • 9 Community-Acquired Pneumonia Severity Index (PSI) for Adults. https://www.merckmanuals.com/en-ca/professional/multimedia/clinical-calculator/community-acquired-pneumonia-severity-index-psi-for-adults
    PubMed
  • 10 Metlay JP, Waterer GW, Long AC. et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200: e45-e67
    Google Scholar
  • 11 Diabetes Society of Chinese Medical Association. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chinese J Diabetes 2021; 13: 315-409
    PubMedGoogle Scholar
  • 12 Timmer JR, Hoekstra M, Nijsten MW. et al. Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention. Circulation 2011; 124: 704-711
    CrossrefPubMedGoogle Scholar
  • 13 Klekotka RB, Mizgala E, Krol W.. The etiology of lower respiratory tract infections in people with diabetes. Pneumonol Alergol Pol 2015; 83: 401-408
    PubMedGoogle Scholar
  • 14 Casqueiro J, Casqueiro J, Alves C.. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab 2012; 16 Suppl 1 S27-S36
    CrossrefPubMedGoogle Scholar
  • 15 Hulme KD, Gallo LA, Short KR.. Influenza virus and glycemic variability in diabetes: A killer combination?. Front Microbiol 2017; 8: 861
    CrossrefPubMedGoogle Scholar
  • 16 Ren W, Zhu Y, Lan J. et al. Susceptibilities of human ACE2 genetic variants in coronavirus infection. J Virol 2022; 96: e0149221
    CrossrefPubMedGoogle Scholar
  • 17 Brufsky A.. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. J Med Virol 2020; 92: 770-775
    CrossrefPubMedGoogle Scholar
  • 18 Philips BJ, Meguer JX, Redman J. et al. Factors determining the appearance of glucose in upper and lower respiratory tract secretions. Intensive Care Med 2003; 29: 2204-2210
    CrossrefPubMedGoogle Scholar
  • 19 Roncon L, Zuin M, Rigatelli G. et al. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol 2020; 127: 104354
    CrossrefPubMedGoogle Scholar
  • 20 Dandachi D, Rodriguez-Barradas MC.. Viral pneumonia: Etiologies and treatment. J Investig Med 2018; 66: 957-965
    CrossrefPubMedGoogle Scholar
  • 21 Lim YK, Kweon OJ, Kim HR. et al. Impact of bacterial and viral coinfection in community-acquired pneumonia in adults. Diagn Microbiol Infect Dis 2019; 94: 50-54
    CrossrefPubMedGoogle Scholar
  • 22 Duan J, Wu Y, Liu C. et al. Deleterious effects of viral pneumonia on cardiovascular system. Eur Heart J 2020; 41: 1833-1838
    CrossrefPubMedGoogle Scholar
  • 23 Zaragoza R, Vidal-Cortés P, Aguilar G. et al. Update of the treatment of nosocomial pneumonia in the ICU. Crit Care 2020; 24: 383
    CrossrefPubMedGoogle Scholar
  • 24 Pérez-Calatayud ÁA, Guillén-Vidaña A, Fraire-Félix IS. et al. Metabolic control in the critically ill patient an update: Hyperglycemia, glucose variability hypoglycemia and relative hypoglycemia. Cir 2017; 85: 93-100
    PubMedGoogle Scholar
  • 25 Hetta HF, Ez-Eldeen ME, Mohamed GA. et al. Visfatin serum levels in obese type 2 diabetic patients: Relation to proinflammatory cytokines and insulin resistance. Egypt J Immunol 2018; 25: 141-151
    PubMedGoogle Scholar
  • 26 Rau CS, Wu SC, Chen YC. et al. Stress-induced hyperglycemia in diabetes: A cross-sectional analysis to explore the definition based on the Trauma Registry Data. Int J Environ Res Public Health 2017; 14: 1527
    CrossrefPubMedGoogle Scholar
  • 27 Trevelin SC, Carlos D, Beretta M. et al. Diabetes mellitus and sepsis: A challenging association. Shock 217 47: 276-287
    CrossrefPubMedGoogle Scholar
  • 28 McAlister FA, Majumdar SR, Blitz S. et al. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care 2005; 28: 810-815
    CrossrefPubMedGoogle Scholar
  • 29 van Crevel R, van de Vijver S, Moore DAJ.. The global diabetes epidemic: What does it mean for infectious diseases in tropical countries?. Lancet Diabetes Endocrinol 2017; 5: 457-468
    CrossrefPubMedGoogle Scholar
  • 30 Stegenga ME, van der Crabben SN, Dessing MC. et al. Effect of acute hyperglycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cytokine production and neutrophil function in humans. Diabet Med 2008; 25: 157-164
    CrossrefPubMedGoogle Scholar
  • 31 Liu J.. Impact of diabetes mellitus on pneumonia mortality in a senior population: Results from the NHANES III follow-up study. J Geriatr Cardiol 2013; 10: 267-271
    PubMedGoogle Scholar
  • 32 Jensen AV, Egelund GB, Andersen SB. et al. The impact of blood glucose on community-acquired pneumonia: A retrospective cohort study. ERJ Open Res 2017; 3: 00114-2016
    CrossrefPubMedGoogle Scholar
  • 33 Clotman K, Twickler MB.. Diabetes or endocrinopathy admitted in the COVID-19 ward. Eur J Clin Invest 2020; 50: e13262
    CrossrefPubMedGoogle Scholar
  • 34 Umpierrez GE, Isaacs SD, Bazargan N. et al. Hyperglycemia: An independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002; 87: 978-982
    CrossrefPubMedGoogle Scholar
  • 35 Santa CA, Mendes-Frias A, Oliveira AI. et al. Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia. Front Immunol 2021; 12: 613422
    CrossrefPubMedGoogle Scholar